A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
Public ClinicalTrials.gov record NCT01285323. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
Study identification
- NCT ID
- NCT01285323
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 464 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2011 (Type not available)
- Primary completion
- Apr 2014 (Actual)
- Completion
- Apr 2014 (Actual)
- Last update posted
- Nov 9, 2021
2011 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 48 | Mobile | Alabama | — | — |
| Teva Investigational Site 41 | Fresno | California | — | — |
| Teva Investigational Site 59 | Long Beach | California | — | — |
| Teva Investigational Site 47 | Denver | Colorado | — | — |
| Teva Investigational Site 28 | Waterbury | Connecticut | — | — |
| Teva Investigational Site 53 | Clearwater | Florida | — | — |
| Teva Investigational Site 27 | Miami | Florida | — | — |
| Teva Investigational Site 25 | Lawrenceville | Georgia | — | — |
| Teva Investigational Site 57 | Metairie | Louisiana | — | — |
| Teva Investigational Site 46 | Bangor | Maine | — | — |
| Teva Investigational Site 40 | St Louis | Missouri | — | — |
| Teva Investigational Site 67 | Fort Mill | South Carolina | — | — |
| Teva Investigational Site 44 | Dallas | Texas | — | — |
| Teva Investigational Site 69 | El Paso | Texas | — | — |
| Teva Investigational Site 45 | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01285323, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01285323 live on ClinicalTrials.gov.